Abu Dhabi announces strategic partnership to advance personalised medicine and genomics

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding (MoU) with AbbVie Biopharmaceutical and M42 to elevate collaborative efforts in tailoring personalised medicine and genomics in Abu Dhabi, the capital of the United Arab Emirates (UAE). M42 is a first-of-its-kind, tech-enabled, integrated healthcare company created through the coming together of G42 Healthcare and Mubadala Health.

The three parties aim to advance precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer. DoH seeks to drive research that will contribute to policy changes and guideline implementation which will enable broader patient access to innovative approaches in healthcare.

The strategic cooperation aims to maximise on the Emirate's unique genomics programme and translate scientific advancements into tangible patient benefits, focusing on precision medicine tailored to individual needs.

The MoU was signed by Dr Asma Al Mannaei, Executive Director of the Research and Innovation Center at the Department of Health – Abu Dhabi (DoH), Francesco Redivo, Senior Director at G42 Healthcare, a M42 company, and Hala Dalle, Medical Director Gulf & Levant at AbbVie Biopharmaceutical at the AbbVie Bioresearch Center in Boston.